Loading
EPHA8 (Ephrin type-A receptor 8) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours and Thyroid cancer.
Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells. The signalling pathway downstream of the receptor is referred to as forward signalling while the signalling pathway downstream of the ephrin ligand is referred to as reverse signalling. The GPI-anchored ephrin-A EFNA2, EFNA3, and EFNA5 are able to activate EPHA8 through phosphorylation.
Open Targets scores its association with cancer at 0.59 (direct and indirect evidence; datatypes literature 0.62, genetic association 0.00, clinical 0.93).
In plain words · EPHA8 (Ephrin type-A receptor 8) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours and Thyroid cancer.
EPHA8 (Ephrin type-A receptor 8) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours and Thyroid cancer.
Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells.
No product in this corpus aims at EPHA8 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA EPHA8: RNA tissue enriched (choroid plexus 32 nTPM); no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Neuroendocrine tumours, Thyroid cancer); Open Targets associates it with 1 specific cancer type at or above 0.5 (medullary thyroid gland carcinoma). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas EPHA8 tissue; Open Targets ENSG00000070886 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Chan et al, Oncogene, 1991, "eek and erk, new members of the eph subclass of receptor protein-tyrosine kinases". Source.
Sources: HGNC HGNC:3391 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P29322 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000070886 (association with cancer (MONDO_0004992) 0.59; per-cancer scores at or above 0.5: thyroid cancer 0.56, neuroendocrine neoplasm 0.62 (GraphQL API, CC0))
Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells. The signalling pathway downstream of the receptor is referred to as forward signalling while the signalling pathway downstream of the ephrin ligand is referred to as reverse signalling. The GPI-anchored ephrin-A EFNA2, EFNA3, and EFNA5 are able to activate EPHA8 through phosphorylation. With EFNA5 may regulate integrin-mediated cell adhesion and migration on fibronectin substrate but also neurite outgrowth. During development of the nervous system also plays a role in axon guidance. Downstream effectors of the EPHA8 signalling pathway include FYN which promotes cell adhesion upon activation by EPHA8 and the MAP kinases in the stimulation of neurite outgrowth. Location: Cell membrane; Cell projection; Early endosome membrane (UniProt). Locus 1p36.12 (HGNC).
RNA: tissue enriched (choroid plexus 32 nTPM), detected in some normal tissues.
No normal tissue stained high.
RNA cancer enhanced: Testicular Germ Cell Tumor 1 pTPM.
No cancer stained high; medium in breast cancer, colorectal cancer, liver cancer, melanoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"EPHA8" OR ABSTRACT:"EPHA8" OR TITLE:"EPH receptor A8" OR ABSTRACT:"EPH receptor A8" OR TITLE:"Ephrin type-A receptor 8" OR ABSTRACT:"Ephrin type-A receptor 8" OR TITLE:"Hek3" OR ABSTRACT:"Hek3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EPHA8, not a curated reading list.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
Shares Thyroid cancer, Open Targets Platform.